The outlook of companies tied to Sildenafil's legacy presents a complex investment picture . While the initial surge generated substantial gains, generic alternatives have significantly diminished market share . Investing in related pharmaceutical businesses now requires a thorough assessment of intellectual property safeguards, evolving patient sh